In his November podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an article and accompanying commentary on the US Food and Drug Administration’s re-approval of gefitinib for the treatment of patients with EGFR-mutated lung cancer. (The drug’s original 2003 approval had been withdrawn in 2011 after subsequent findings failed to show a survival advantage.) He also comments on a line-up of clinical and supportive oncology articles reporting on a modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting; caregivers’ attitudes about their roles in promoting exercise among patients with late-stage lung cancer; the impact of inpatient radiation on length of stay and health care costs; and a study of patients with incurable cancer by Japanese investigators who examined differences in the timing of palliative chemotherapy cessation between patients in a local hospital and patients who transitioned to a local hospital from a tertiary medical center. The final item details a case of treatment-related MDS/AML in a patient after receiving therapy for large-cell neuroendocrine lung cancer.
Click on the download icon at the top of this introduction to listen to the podcast.